Brief: Algernon Announces 50% Enrollment In Multinational 2B/3 Human Study Of Ifenprodil For Treatment Of Covid-19
22/09/2020 14:50
Sept 22 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON ANNOUNCES 50% ENROLLMENT IN MULTINATIONAL 2B/3
HUMAN
STUDY OF IFENPRODIL FOR TREATMENT OF COVID-19
Source text for Eikon: ID:nGNX2cDlWR
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement